Brooks Laboratories Limited (BOM:533543)
61.88
+2.48 (4.18%)
At close: Aug 21, 2026
Brooks Laboratories Revenue
Brooks Laboratories had revenue of 229.61M INR in the quarter ending June 30, 2026, a decrease of -10.00%. This brings the company's revenue in the last twelve months to 831.87M, down -7.71% year-over-year. In the fiscal year ending March 31, 2026, Brooks Laboratories had annual revenue of 857.38M with 3.85% growth.
Revenue (ttm)
831.87M
Revenue Growth
-7.71%
P/S Ratio
2.12
Revenue / Employee
2.40M
Employees
347
Market Cap
1.77B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 857.38M | 31.82M | 3.85% |
| Mar 31, 2025 | 825.57M | 30.71M | 3.86% |
| Mar 31, 2024 | 794.86M | 162.81M | 25.76% |
| Mar 31, 2023 | 632.05M | -279.80M | -30.69% |
| Mar 31, 2022 | 911.85M | 139.38M | 18.04% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bilcare | 7.34B |
| Bal Pharma | 3.34B |
| Parnax Lab | 2.52B |
| Sat Kartar Life | 2.01B |
| Lactose (India) | 1.71B |
| Oxygenta Pharmaceutical | 1.35B |
| Coral Laboratories | 968.04M |
| Accretion Pharmaceuticals | 896.27M |